Abstract: Objective To analyze the long-term response of different adjuvant chemotherapies and endocrine-therapies after adjuvant chemotherapy in patients of breast cancer after operation with different Ki-67 expressions. Methods A total of 694 patients with breast cancer were collected from January 2008 to December 2009. All the patients accepted anthracycline-based or sequential taxane chemotherapy and 261 menopausal patients in them with ER positive expression accepted selective estrogen receptor modulator（SERM）or aromatase inhibitor（AI）after adjuvant chemotherapy. On the occasion of different Ki-67 expressions，the correlation of disease-free survival（DFS），overall survival（OS）with different adjuvant chemotherapies and endocrine therapies after adjuvant chemotherapy were analyzed by statistics.
Results（1）In 527 cases of Ki-67 positive expression，the median DFS and OS were 37.0 and 38.0 months. For those accepted anthracycline-based and sequential taxane regimen，the median DFS were 36.5 months and 38.0 months（P=0.046），and the median OS were 38.0 months and 39.0 months（P=0.045）.In 167 cases of Ki-67 negative expression，the median DFS and OS were 49.4 and 51.5 months，and the median DFS and OS between anthracycline-based and sequential taxane regimen had no statistic significance. In 4 types of Ki-67 and ER status，only in patients of Ki-67+ER-，the median DFS（30.5 months vs.35.9 months，P=0.030）and median OS（39.2 months vs. 42.1 months，P=0.160）for anthracycline-based and sequential taxane regime had statistic significance.（2）In 261 menopausal patients with ER positive expression，200 cases of Ki-67 were positive expressed with the median DFS and OS of 38.0 and 39.0 months. While in 61 cases of Ki-67 negative expression，the median DFS and OS were 52.0 and 53.3 months. The median OS and PFS had no significance in patients accepted SERM or AI with different Ki-67 expression. Conclusion In the adjuvant chemotherapy of breast cancer after operation，the efficacy of sequential taxanes regimen is superior to anthracycline-based regimen in Ki-67 positive expressed patients. In menopausal patients with ER positive expression，the efficacy of SERM is similar to that of AI with different Ki-67 expression.